Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. Janka-Schaub GE, et al. Among authors: veerman aj. Klin Padiatr. 1999 Jul-Aug;211(4):233-8. doi: 10.1055/s-2008-1043794. Klin Padiatr. 1999. PMID: 10472556 Clinical Trial. German.
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ, Janka-Schaub GE. Den Boer ML, et al. Among authors: veerman aj. J Clin Oncol. 2003 Sep 1;21(17):3262-8. doi: 10.1200/JCO.2003.11.031. J Clin Oncol. 2003. PMID: 12947061
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL, Pieters R, Hoelzer D, Slater RM, den Boer ML, Loonen AH, Harbott J, Janka-Schaub GE, Ludwig WD, Ossenkoppele GJ, van Wering ER, Veerman AJ; Dutch and German Leukemia Study Groups. Ramakers-van Woerden NL, et al. Among authors: veerman aj. Med Pediatr Oncol. 2002 Jun;38(6):379-86. doi: 10.1002/mpo.10087. Med Pediatr Oncol. 2002. PMID: 11984797
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Zwaan CM, Kaspers GJ, Pieters R, Hählen K, Janka-Schaub GE, van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJ. Zwaan CM, et al. Among authors: veerman aj. Blood. 2002 Jan 1;99(1):245-51. doi: 10.1182/blood.v99.1.245. Blood. 2002. PMID: 11756178 Free article.
Cellular drug resistance in childhood leukemia.
Veerman AJ, Kaspers GJ, Pieters R. Veerman AJ, et al. Ann Hematol. 1994;69 Suppl 1:S31-4. doi: 10.1007/BF01757352. Ann Hematol. 1994. PMID: 8061109 Review.
242 results